Revolution Medicines R&D chief Steve Kelsey to step down as senior adviser July 1

Revolution Medicines

RVMD

0.00

Revolution Medicines named Steve Kelsey senior advisor to the CEO effective July 1, 2026, from president of research and development.
Kelsey plans to retire January 4, 2027; the company expects to appoint him to the board at that time.
R&D leadership shifts July 1, 2026; Chief Development Officer Alan Sandler continues to lead development.
Chief Scientific Officer Jan Smith will oversee research under the new structure.
Xiaolin Wang becomes executive vice president, integrated portfolio strategy and management, adding oversight of pharmaceutical development, manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750116) on June 22, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.